Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia

Tibor J. Kovacsovics, Alice Mims, Mohamed Salama, Jeremy Pantin, Narayanam Rao, Ken M. Kosak, Peter Ahorukomeye, Martha J. Glenn, Michael W.N. Deininger, Kenneth M. Boucher, Linda M. Bavisotto, Gerardo Gutierrez-Sanchez, Thomas P. Kennedy, Stephen G. Marcus, Paul J. Shami

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Relapses in acute myelogenous leukemia (AML) are a result of quiescent leukemic stem cells (LSCs) in marrow stromal niches, where they resist chemotherapy. LSCs employ CXCL12/CXCR4 to home toward protective marrow niches. Heparin disrupts CXCL12-mediated sequestration of cells in the marrow. CX-01 is a low-anticoagulant heparin derivative. In this pilot study, we combined CX-01 with chemotherapy for the treatment of AML. Induction consisted of cytarabine and idarubicin (7 + 3) with CX-01. Twelve patients were enrolled (median age, 56 years; 3 women). Three, 5, and 4 patients had good-, intermediate-, and poor-risk disease, respectively. Day 14 bone marrows were available on 11 patients and were aplastic in all without detectable leukemia. Eleven patients (92%) had morphologic complete remission after 1 induction (CR1). Eight patients were alive at a median follow-up of 24 months (4 patients in CR1). Three patients received an allogeneic stem cell transplant in CR1. Median disease-free survival was 14.8 months. Median overall survival was not attained at the maximum follow-up time of 29.4 months. No CX-01-associated serious adverse events occurred. Median day to an untransfused platelet count of at least 20 × 109/L was 21. CX-01 is well tolerated when combined with intensive therapy for AML and appears associated with enhanced count recovery and treatment efficacy.

Original languageEnglish (US)
Pages (from-to)381-389
Number of pages9
JournalBlood Advances
Volume2
Issue number4
DOIs
StatePublished - Feb 27 2018
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Anticoagulants
Heparin
Drug Therapy
Bone Marrow
Stem Cells
Therapeutics
Idarubicin
Cytarabine
Platelet Count
Disease-Free Survival
Leukemia
Transplants
Recurrence
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia. / Kovacsovics, Tibor J.; Mims, Alice; Salama, Mohamed; Pantin, Jeremy; Rao, Narayanam; Kosak, Ken M.; Ahorukomeye, Peter; Glenn, Martha J.; Deininger, Michael W.N.; Boucher, Kenneth M.; Bavisotto, Linda M.; Gutierrez-Sanchez, Gerardo; Kennedy, Thomas P.; Marcus, Stephen G.; Shami, Paul J.

In: Blood Advances, Vol. 2, No. 4, 27.02.2018, p. 381-389.

Research output: Contribution to journalArticle

Kovacsovics, TJ, Mims, A, Salama, M, Pantin, J, Rao, N, Kosak, KM, Ahorukomeye, P, Glenn, MJ, Deininger, MWN, Boucher, KM, Bavisotto, LM, Gutierrez-Sanchez, G, Kennedy, TP, Marcus, SG & Shami, PJ 2018, 'Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia', Blood Advances, vol. 2, no. 4, pp. 381-389. https://doi.org/10.1182/bloodadvances.2017013391
Kovacsovics, Tibor J. ; Mims, Alice ; Salama, Mohamed ; Pantin, Jeremy ; Rao, Narayanam ; Kosak, Ken M. ; Ahorukomeye, Peter ; Glenn, Martha J. ; Deininger, Michael W.N. ; Boucher, Kenneth M. ; Bavisotto, Linda M. ; Gutierrez-Sanchez, Gerardo ; Kennedy, Thomas P. ; Marcus, Stephen G. ; Shami, Paul J. / Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia. In: Blood Advances. 2018 ; Vol. 2, No. 4. pp. 381-389.
@article{85499e39f7ad4521bf9341bd9c4cca18,
title = "Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia",
abstract = "Relapses in acute myelogenous leukemia (AML) are a result of quiescent leukemic stem cells (LSCs) in marrow stromal niches, where they resist chemotherapy. LSCs employ CXCL12/CXCR4 to home toward protective marrow niches. Heparin disrupts CXCL12-mediated sequestration of cells in the marrow. CX-01 is a low-anticoagulant heparin derivative. In this pilot study, we combined CX-01 with chemotherapy for the treatment of AML. Induction consisted of cytarabine and idarubicin (7 + 3) with CX-01. Twelve patients were enrolled (median age, 56 years; 3 women). Three, 5, and 4 patients had good-, intermediate-, and poor-risk disease, respectively. Day 14 bone marrows were available on 11 patients and were aplastic in all without detectable leukemia. Eleven patients (92{\%}) had morphologic complete remission after 1 induction (CR1). Eight patients were alive at a median follow-up of 24 months (4 patients in CR1). Three patients received an allogeneic stem cell transplant in CR1. Median disease-free survival was 14.8 months. Median overall survival was not attained at the maximum follow-up time of 29.4 months. No CX-01-associated serious adverse events occurred. Median day to an untransfused platelet count of at least 20 × 109/L was 21. CX-01 is well tolerated when combined with intensive therapy for AML and appears associated with enhanced count recovery and treatment efficacy.",
author = "Kovacsovics, {Tibor J.} and Alice Mims and Mohamed Salama and Jeremy Pantin and Narayanam Rao and Kosak, {Ken M.} and Peter Ahorukomeye and Glenn, {Martha J.} and Deininger, {Michael W.N.} and Boucher, {Kenneth M.} and Bavisotto, {Linda M.} and Gerardo Gutierrez-Sanchez and Kennedy, {Thomas P.} and Marcus, {Stephen G.} and Shami, {Paul J.}",
year = "2018",
month = "2",
day = "27",
doi = "10.1182/bloodadvances.2017013391",
language = "English (US)",
volume = "2",
pages = "381--389",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia

AU - Kovacsovics, Tibor J.

AU - Mims, Alice

AU - Salama, Mohamed

AU - Pantin, Jeremy

AU - Rao, Narayanam

AU - Kosak, Ken M.

AU - Ahorukomeye, Peter

AU - Glenn, Martha J.

AU - Deininger, Michael W.N.

AU - Boucher, Kenneth M.

AU - Bavisotto, Linda M.

AU - Gutierrez-Sanchez, Gerardo

AU - Kennedy, Thomas P.

AU - Marcus, Stephen G.

AU - Shami, Paul J.

PY - 2018/2/27

Y1 - 2018/2/27

N2 - Relapses in acute myelogenous leukemia (AML) are a result of quiescent leukemic stem cells (LSCs) in marrow stromal niches, where they resist chemotherapy. LSCs employ CXCL12/CXCR4 to home toward protective marrow niches. Heparin disrupts CXCL12-mediated sequestration of cells in the marrow. CX-01 is a low-anticoagulant heparin derivative. In this pilot study, we combined CX-01 with chemotherapy for the treatment of AML. Induction consisted of cytarabine and idarubicin (7 + 3) with CX-01. Twelve patients were enrolled (median age, 56 years; 3 women). Three, 5, and 4 patients had good-, intermediate-, and poor-risk disease, respectively. Day 14 bone marrows were available on 11 patients and were aplastic in all without detectable leukemia. Eleven patients (92%) had morphologic complete remission after 1 induction (CR1). Eight patients were alive at a median follow-up of 24 months (4 patients in CR1). Three patients received an allogeneic stem cell transplant in CR1. Median disease-free survival was 14.8 months. Median overall survival was not attained at the maximum follow-up time of 29.4 months. No CX-01-associated serious adverse events occurred. Median day to an untransfused platelet count of at least 20 × 109/L was 21. CX-01 is well tolerated when combined with intensive therapy for AML and appears associated with enhanced count recovery and treatment efficacy.

AB - Relapses in acute myelogenous leukemia (AML) are a result of quiescent leukemic stem cells (LSCs) in marrow stromal niches, where they resist chemotherapy. LSCs employ CXCL12/CXCR4 to home toward protective marrow niches. Heparin disrupts CXCL12-mediated sequestration of cells in the marrow. CX-01 is a low-anticoagulant heparin derivative. In this pilot study, we combined CX-01 with chemotherapy for the treatment of AML. Induction consisted of cytarabine and idarubicin (7 + 3) with CX-01. Twelve patients were enrolled (median age, 56 years; 3 women). Three, 5, and 4 patients had good-, intermediate-, and poor-risk disease, respectively. Day 14 bone marrows were available on 11 patients and were aplastic in all without detectable leukemia. Eleven patients (92%) had morphologic complete remission after 1 induction (CR1). Eight patients were alive at a median follow-up of 24 months (4 patients in CR1). Three patients received an allogeneic stem cell transplant in CR1. Median disease-free survival was 14.8 months. Median overall survival was not attained at the maximum follow-up time of 29.4 months. No CX-01-associated serious adverse events occurred. Median day to an untransfused platelet count of at least 20 × 109/L was 21. CX-01 is well tolerated when combined with intensive therapy for AML and appears associated with enhanced count recovery and treatment efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85056610351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056610351&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2017013391

DO - 10.1182/bloodadvances.2017013391

M3 - Article

VL - 2

SP - 381

EP - 389

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 4

ER -